Arun Azad

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma

Cristian Udovicich, Jason Callahan, Mathias Bressel, Wee Loon Ong, Marlon Perera, Ben Tran, Arun Azad, Shankar Haran, Daniel Moon, Sarat Chander, Mark Shaw, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Declan G Murphy, Michael Hofman, Shankar Siva

Journal article  |  2022  |  EUROPEAN UROLOGY OPEN SCIENCE

BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in the neovasculature of renal cell carcinoma (RCC). Howeve..

Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer

Kenneth Chen, Aoife McVey, Veeru Kasivisvanathan, Pocharapong Jenjitranant, Arun Azad, Declan G Murphy

Journal article  |  2022  |  EUROPEAN UROLOGY

Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).

Anis Hamid, Michael S Hofman, Mathias Bressel, Louise Emmett, Anthony M Joshua, Lavinia Anne Spain, Lisa Horvath, Megan Crumbaker, Anupama Pasam, Jason Callahan, Alisa Tubbs, Luisa Fernandez, Richard J Wenstrup, Grace Kong, Jeremy Howard Lewin, Ben Tran, Arun Azad, Joseph D Schonhoft, Rodney J Hicks, Shahneen Sandhu

Conference Proceedings  |  2022  |  Journal of Clinical Oncology

5027 Background: The Phase I PRINCE trial (NCT03658447) is evaluating the efficacy of 177Lu-PSMA-617 plus pembrolizumab for mCRPC..

Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

Arun A Azad, Ben Tran, Ian D Davis, Phillip Parente, Melanie Evans, Shirley Wong, Stephen Brown, Sue Evans, Jeremy Millar, Declan G Murphy, Nathan Papa

Journal article  |  2022  |  INTERNAL MEDICINE JOURNAL

BACKGROUND: Docetaxel has emerged as a standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). Uptake of doceta..

Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.

Angelyn Anton, Sruti Pillai, Marie Christine Semira, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Olivia Baenziger, Peter Gibbs, Ben Tran

Journal article  |  2022  |  BJUI Compass

INTRODUCTION: Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer..

Lu-177-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN) Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

Sarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, Andrew Nguyen, Christopher Rofe, Elizabeth Hovey, Craig Gedye, Edmond M Kwan, Christine Hauser, Arun A Azad, Peter Eu, Andrew J Martin, Anthony M Joshua, Louise Emmett

Journal article  |  2022  |  JOURNAL OF NUCLEAR MEDICINE

177Lu-PSMA-617 is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC). However, treatment resistance ..

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

Blossom Mak, Hui-Ming Lin, Edmond M Kwan, Heidi Fettke, Tran Ben, Ian D Davis, Kate Mahon, Martin R Stockler, Karen Briscoe, Gavin Marx, Alison Zhang, Megan Crumbaker, Winston Tan, Kevin Huynh, Thomas G Meikle, Natalie A Mellett, Andrew J Hoy, Pan Du, Jianjun Yu, Shidong Jia, et al.

Journal article  |  2022  |  BMC MEDICINE

BACKGROUND: Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumo..

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial

Shankar Siva, Mathias Bressel, Simon T Wood, Mark G Shaw, Sherene Loi, Shahneen K Sandhu, Ben Tran, Arun A Azad, Jeremy H Lewin, Katharine E Cuff, Howard Y Liu, Daniel Moon, Jeremy Goad, Lih-Ming Wong, Michael LimJoon, Jennifer Mooi, Sarat Chander, Declan G Murphy, Nathan Lawrentschuk, David Pryor

Journal article  |  2022  |  EUROPEAN UROLOGY

BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an option for oligometastatic clear cell renal cell carcinoma (ccRCC..

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial

Edmond M Kwan, Lavinia Spain, Angelyn Anton, Chun L Gan, Linda Garrett, Deborah Chang, Elizabeth Liow, Caitlin Bennett, Tiantian Zheng, Jianjun Yu, Chao Dai, Pan Du, Shidong Jia, Heidi Fettke, Claire Abou-Seif, Gargi Kothari, Mark Shaw, Phillip Parente, Carmel Pezaro, Ben Tran, et al.

Journal article  |  2022  |  EUROPEAN UROLOGY

BACKGROUND: Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest..

Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).

Heidi Fettke, Christine Hauser, Edmond Michael Kwan, Chao Dai, Tiantian Zheng, Amy Wang, Winston Tan, Pan Du, Nicole Ng, Patricia Bukczynska, Siavash Foroughi, Lisa-Jane K Graham, Lisa Horvath, Kate Lynette Mahon, Shidong Jia, Manish Kohli, Arun Azad

Conference Proceedings  |  2022  |  JOURNAL OF CLINICAL ONCOLOGY

153 Background: The prognostic significance of DDR alterations in mCRPC remains unclear, with conflicting data from prior reports..